2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Radionuclide-Drug Conjugates (RDCs)

Radionuclide-Drug Conjugates (RDCs)

ADC-Related Custom Services

Radionuclide-drug conjugates (RDCs) are one of the most promising development directions for nuclear drug targeted therapy. RDC is composed of targeting element, linker, chelate and radioactive isotope. RDC has advantages in early tumor diagnosis, treatment and postoperative tumor evaluation. The same ligand can be connected to nuclides used for disease diagnosis and treatment respectively, promoting the integration of diagnosis and treatment of RDC drugs. This entry provides molecular intermediates that can be used in the synthesis and research of RDC.

Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products:

Radionuclide-Drug Conjugates (RDCs) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-D2363
    DOTA.SA.FAPi TFA
    		99.26%
    DOTA.SA.FAPi TFA inhibits fibroblast activation protein (FAP) with an IC50 of 0.9 nM. DOTA.SA.FAPi TFA targets protease PREP with an IC50 of 5.4 μM. DOTA.SA.FAPi TFA can be used a PET tracer, when labeled with 68Ga, and used for research about cancer. DOTA.SA.FAPi (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA.SA.FAPi TFA
  • HY-136641
    NOTA-FAPI
    		99.26%
    NOTA-FAPI is a fibroblast activation protein (FAP) inhibitor. NOTA-FAPI can be used as a probe for FAP-targeted tumour imaging. NOTA-FAPI has good tumour detection efficacy and excellent imaging quality.
    NOTA-FAPI
  • HY-W046355
    Fmoc-D-Dap(Boc)-OH
    		99.56%
    Fmoc-D-Dap(Boc)-OH is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize bioactive peptide mimetics, such as DOTA-modified peptides and their metal chelates with cancer diagnostic effects.
    Fmoc-D-Dap(Boc)-OH
  • HY-W539916
    Azido-mono-amide-DOTA
    		99.96%
    Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.
    Azido-mono-amide-DOTA
  • HY-P2218
    Anditixafortide
    		99.27%
    Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative. Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Anditixafortide
  • HY-W755033
    NH2-PEG4-DOTA
    NH2-PEG4-DOTA is a bifunctional, DOTA-type metal chelator. NH2-PEG4-DOTA can be conjugated with Dextran for quantitative analysis in the presence of a highly luminescent complex. NH2-PEG4-DOTA can also bind to radionuclides to prepare radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    NH2-PEG4-DOTA
  • HY-P5290
    HYNIC-PSMA
    		99.81%
    HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as 188Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research. HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    HYNIC-PSMA
  • HY-100138
    2-Aminoethyl-mono-amide-DOTA-tris(tBu ester)
    		98.0%
    2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) is a metal chelator precursor containing a DOTA macrocyclic structure. DOTA can form highly stable complexes with metal ions (such as 68Ga, 177Lu) through four nitrogen atoms and four carboxylic acid groups to mediate targeted delivery of radionuclides. The tert-butyl ester group (tBu ester) of 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) also protects the carboxylic acid group during synthesis, and forms a free carboxyl group after deprotection reaction for coupling with targeting molecules (such as antibodies, peptides). 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) may be combined with tumor pre-targeting systems through bioorthogonal reactions (such as reverse electron demand Diels-Alder reaction) to study radioactive imaging or therapy of tumor tissues, and is mainly used in tumor pre-targeting research in the field of nuclear medicine.
    2-Aminoethyl-mono-amide-DOTA-tris(tBu ester)
  • HY-P10732
    DOTA-cyclo(RGDfK)
    		98.10%
    DOTA-cyclo(RGDfK) is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    DOTA-cyclo(RGDfK)
  • HY-164569
    NH2 DOTA-GA
    		99.95%
    NH2 DOTA-GA is a DOTA-based metal chelator that can be used to prepare radionuclide drug conjugates (RDCs) whose carboxylic acid groups can complex metal ions. For example, NH2 DOTA-GA complexes Gd(III) ions.
    NH2 DOTA-GA
  • HY-W717743
    DOTAM-mono-acid
    		98.0%
    DOTAM-mono-acidis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-mono-acid can be used for conjugation of peptides and radionuclides.
    DOTAM-mono-acid
  • HY-P5292A
    HYNIC-iPSMA TFA
    		98.05%
    HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity. HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    HYNIC-iPSMA TFA
  • HY-P10273A
    DOTA-Octreotide TFA
    		99.30%
    DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-Octreotide TFA
  • HY-P2112
    DOTA-NOC
    		99.22%
    DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging. DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-NOC
  • HY-167830
    SDM-8
    		99.79%
    SDM-8 is a difluoro-analog of UCB-J (HY-136873).SDM-8 shows high SV2A binding affinity with a Ki of 0.58 nM. SDM-8 can be used in the study of Alzheimer's disease.
    SDM-8
  • HY-18670
    HQ-415
    		98.05%
    HQ-415 is a biologically active metal chelator related to Clioquinol (HY-14603), with an EC50 of 15 μM.
    HQ-415
  • HY-P5126A
    DOTA-LM3 TFA
    		99.30%
    DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis. DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-LM3 TFA
  • HY-W782078
    Butyne-DOTA
    Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.
    Butyne-DOTA
  • HY-P10945
    FAP targeting peptide for FXX489
    		99.49%
    FAP targeting peptide for FXX489 is the polypeptide part of Unlabeled FXX489 (HY-P10944). Unlabeled FXX489 is a fibroblast activation protein (FAP)-targeting ligand.
    FAP targeting peptide for FXX489
  • HY-159180
    p-NCS-Bz-NODA-GA
    		99.46%
    p-NCS-Bz-NODA-GA is a bifunctional chelator.
    p-NCS-Bz-NODA-GA
Radionuclide-Drug Conjugates (RDCs) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.